UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of 3‑(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl‑3H‑imidazo[4,5‑b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Journal of medicinal chemistry, 2016-07, Vol.59 (13), p.6455-6469

2016

Volltextzugriff (PDF)

Asymmetric Catalysis of the Strecker Amino Acid Synthesis by a Cyclic Dipeptide

Journal of the American Chemical Society, 1996-05, Vol.118 (20), p.4910-4911

1996

Volltextzugriff (PDF)

Retraction of “Asymmetric Catalysis of the Strecker Amino Acid Synthesis by a Cyclic Dipeptide

Journal of the American Chemical Society, 2023-07, Vol.145 (27), p.15016-15016

2023

Volltextzugriff (PDF)

Abstract 1234: Galeterone-induced degradation of the androgen receptor involves inhibition of deubiquitinating enzymes

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1234-1234

2016

Volltextzugriff (PDF)

Correlation of galeterone-induced degradation of the androgen receptor with inhibition of a deubiquitinating enzyme

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.345-345

2016

Volltextzugriff (PDF)

Galeterone to target proteasomal degradation of the androgen receptor in prostate tumor cells: A novel mechanism of action for treatment of AR-V7+ CRPC

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14092-e14092

2016

Volltextzugriff (PDF)

The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival

Oncotarget, 2018-05, Vol.9 (38), p.24992-25007

2018

Volltextzugriff (PDF)

Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3 H -imidazo[4,5- b ]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Journal of medicinal chemistry, 2016-07, Vol.59 (13), p.6455-6469

2016

Volltextzugriff (PDF)

Abstract B270: Discovery and preliminary characterization of novel tyrosine kinase inhibitors with selectivity to BTK

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.B270-B270

2013

Volltextzugriff (PDF)

Abstract LB-1: Discovery and optimization of orally bioavailable, selective and potent ATP-independent Akt inhibitors

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.LB-1-LB-1

2012

Volltextzugriff (PDF)

Abstract 4501: Development and biological annotation of a novel RAF inhibitor amenable for clinical evaluation against BRAF (V600E)-harboring human tumors

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4501-4501

2010

Volltextzugriff (PDF)

Discovery of novel selective Sigma-1 ligands as cognitive enhancers

MedChemComm, 2011-07, Vol.2 (7), p.655-660

2011

Volltextzugriff (PDF)

Discovery of an Opioid κ Receptor Selective Pure Antagonist from a Library of N-Substituted 4β-Methyl-5-(3-hydroxyphenyl)morphans

Journal of medicinal chemistry, 2002-08, Vol.45 (16), p.3524-3530

2002

Volltextzugriff (PDF)

Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphans

Journal of medicinal chemistry, 2002-08, Vol.45 (16), p.3524-3530

2002

Volltextzugriff (PDF)

Discovery of an opioid κK receptor selective pure antagonist from a library of N-substituted 4β-methyl-5-(3-hydroxyphenyl)morphans

Journal of medicinal chemistry, 2002, Vol.45 (16), p.3524-3530

2002

Volltextzugriff (PDF)

Enantioselective syntheses of aldohexoses using macrocyclic stereocontrol

Namdev, Nivedita D

1997

Volltextzugriff (PDF)

Pyridine and pyrimidine ring syntheses from 4-(4-morpholino)-3-pentenone and from ethyl 3-(4-morpholino)-2-butenoate

Journal of heterocyclic chemistry, 1993-12, Vol.30 (6), p.1513-1516

1993

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(17)
Dissertationen
(1)

Sprache

Englisch
(18)

Erscheinungsjahr

n.n

Kollektion

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Medicinal Chemistry
(6)
Cancer Research
(3)
Journal Of Clinical Oncology
(2)
Journal Of The American Chemical Society
(2)
Journal Of Heterocyclic Chemistry
(1)
Medchemcomm
(1)
Molecular Cancer Therapeutics
(1)
Oncotarget
(1)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery of 3‑(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl‑3H‑imidazo[4,5‑b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Asymmetric Catalysis of the Strecker Amino Acid Synthesis by a Cyclic Dipeptide

Retraction of “Asymmetric Catalysis of the Strecker Amino Acid Synthesis by a Cyclic Dipeptide

Abstract 1234: Galeterone-induced degradation of the androgen receptor involves inhibition of deubiquitinating enzymes

Correlation of galeterone-induced degradation of the androgen receptor with inhibition of a deubiquitinating enzyme

Galeterone to target proteasomal degradation of the androgen receptor in prostate tumor cells: A novel mechanism of action for treatment of AR-V7+ CRPC

The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival

Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors

Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3 H -imidazo[4,5- b ]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Abstract B270: Discovery and preliminary characterization of novel tyrosine kinase inhibitors with selectivity to BTK

Abstract LB-1: Discovery and optimization of orally bioavailable, selective and potent ATP-independent Akt inhibitors

Abstract 4501: Development and biological annotation of a novel RAF inhibitor amenable for clinical evaluation against BRAF (V600E)-harboring human tumors

Discovery of novel selective Sigma-1 ligands as cognitive enhancers

Discovery of an Opioid κ Receptor Selective Pure Antagonist from a Library of N-Substituted 4β-Methyl-5-(3-hydroxyphenyl)morphans

Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphans

Discovery of an opioid κK receptor selective pure antagonist from a library of N-substituted 4β-methyl-5-(3-hydroxyphenyl)morphans

Enantioselective syntheses of aldohexoses using macrocyclic stereocontrol

Pyridine and pyrimidine ring syntheses from 4-(4-morpholino)-3-pentenone and from ethyl 3-(4-morpholino)-2-butenoate

Suchergebnisse filtern